Stock HIKAL HIKAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Hikal Limited

Equities

HIKAL

INE475B01022

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:21:50 2024-04-23 am EDT 		5-day change 1st Jan Change
314.8 INR -1.66% Intraday chart for Hikal Limited +4.62% +3.72%
Apr. 08 Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million. CI
Apr. 01 Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors CI

Business Summary

Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.

Sales per Business

INR in Million2022Weight2023Weight Delta
Pharmaceuticals
55.1 %
11,297 58.2 % 11,152 55.1 % -1.29%
Crop Protection
44.9 %
8,130 41.8 % 9,079 44.9 % +11.67%

Sales per region

INR in Million2022Weight2023Weight Delta
India
32.4 %
5,285 27.2 % 6,546 32.4 % +23.85%
Europe
28.5 %
4,593 23.6 % 5,772 28.5 % +25.68%
South East Asia
21.4 %
2,218 11.4 % 4,321 21.4 % +94.81%
United States and Canada
16.6 %
3,130 16.1 % 3,356 16.6 % +7.20%
Others
1.2 %
4,201 21.6 % 235 1.2 % -94.39%

Managers

Managers TitleAgeSince
Sameer Jai Hiremath CEO
 Chief Executive Officer 50 95-12-31
Jai Hiremath FOU
 Founder 76 88-07-07
Kuldeep Jain DFI
 Director of Finance/CFO - -
Rajasekhar Reddy
- -
Vimal Deep Kulshrestha PRN
 Corporate Officer/Principal 59 -
Anish Swadi PRN
 Corporate Officer/Principal - 04-12-31
Ratish Jha HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Jai Hiremath FOU
 Founder 76 88-07-07
Sameer Jai Hiremath CEO
 Chief Executive Officer 50 95-12-31
Sugandha Jai Hiremath BRD
 Director/Board Member 72 92-02-04
Berjis Minoo Desai BRD
 Director/Board Member 67 23-09-30
Vinnakota R. Kaundinya BRD
 Director/Board Member 68 23-09-30
Amit Babasaheb Kalyani BRD
 Director/Board Member 48 10-07-21
Sachdeva Bhasin BRD
 Director/Board Member - 19-07-31
Ravi Kapoor BRD
 Director/Board Member 63 Jan. 10
Shrikrishna Kiran Adivarekar BRD
 Director/Board Member 41 21-12-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 123,300,750 38,132,111 ( 30.93 %) 0 30.93 %

Shareholders

NameEquities%Valuation
KALYANI INVESTMENT COMPANY LIMITED
31.36 %
38,667,375 31.36 % 123 M ₹
Shri Badrinath Investment Pvt Ltd.
16.15 %
19,914,862 16.15 % 63 M ₹
Shri Rameshwara Investment Ltd.
7.956 %
9,810,000 7.956 % 31 M ₹
Sugandha Jai Hiremath
7.841 %
9,667,500 7.841 % 31 M ₹
Tata Asset Management Ltd.
2.676 %
3,300,000 2.676 % 10 M ₹
BF INVESTMENT LIMITED
2.655 %
3,273,375 2.655 % 10 M ₹
Norges Bank Investment Management
2.059 %
2,539,138 2.059 % 8 M ₹
Jai Hiremath
1.087 %
1,340,625 1.087 % 4 M ₹
Thélème Partners LLP
1.048 %
1,292,203 1.048 % 4 M ₹
Ekdant Investments Pvt Ltd.
0.3194 %
393,802 0.3194 % 1 M ₹

Company contact information

Hikal Ltd.

Great Eastern Chambers, 6 Floor Sector 11, Navi Mumbai

400614, Mumbai

+91 22 6277 0299

http://www.hikal.com
address Hikal Limited(HIKAL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Hikal Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
314.8 INR
Average target price
330 INR
Spread / Average Target
+4.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HIKAL LIMITED Stock Hikal Limited
+3.72% 473M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.65% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.33% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.13% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
NOVARTIS AG Stock Novartis AG
+4.80% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.80% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HIKAL Stock
  4. Company Hikal Limited